title: Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.
abstract: Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are main effecter cells in cellular immunity against tumor cells. T-cell immunotherapy is based on the assumption that tumor(-associated) antigen (TA) peptides are correctly presented by HLA class I molecules on target tumor cells, and NK cell immunotherapy is based on the hypothesis that cell surface TAs or ligands for NK receptors are widely expressed in tumor cells. However, human tumor cells often lose HLA class I molecules, and target cell ligands for NK receptors are not always expressed in human tumor cells. These altered HLA class I phenotypes and non-ubiquitous expression of NK receptor ligands constitute the major tumor escape mechanism facing tumor-specific CTL and/or NK cell mediated responses. These facts also indicate that it is not easy to eliminate the target tumors only by activating tumor-specific CTLs or NK cells with cancer vaccine treatments. On the other hand, it is easily confirmed by immunohistochemistry whether or not antibody-recognized TAs exist on the cell surface of target tumor cells. Therefore, endowing CTLs or NK cells with antigen-binding specificity of anti-TA antibody is a promising approach for re-targeting the activities of these effector cells to tumor cells in an HLA-independent manner. This review summarizes the following four new strategies for re-targeting CTLs or NK cells to carcinoembryonic-antigen-expressing tumor cells: (1) bispecific antibody technology; (2) antibody-cytokine fusion protein technology; (3) chimeric immune receptor technology, and (4) antibody-HLA/peptide complex technology.
authors.affiliation: Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan. kurokima@fukuoka-u.ac.jp
authors.forename: Masahide
authors.initials: M
authors.lastname: Kuroki
authors.forename: Motomu
authors.initials: M
authors.lastname: Kuroki
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shibaguchi
authors.forename: Adel
authors.initials: A
authors.lastname: Badran
authors.forename: Ken
authors.initials: K
authors.lastname: Hachimine
authors.forename: Jitian
authors.initials: J
authors.lastname: Zhang
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Kinugasa
mesh_terms: D001666:Binding Sites, Antibody; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen